Poly Medicure Q1 FY27: Revenue up 30.3%, PAT down

Key takeaways from the quarter

Poly Medicure reported strong consolidated revenue growth in Q1 FY27, supported by international demand and the consolidation of acquired businesses. Revenue from operations rose to ₹525.4 crore from ₹403.2 crore in Q1 FY26, a 30.3% year-on-year increase. Operating EBITDA increased to ₹126.7 crore from ₹107.6 crore, up 17.7% YoY. Despite the EBITDA growth, the consolidated EBITDA margin fell to 24.1% from 26.7%, reflecting higher employee and other operating costs in a quarter that included acquired entities. Consolidated profit after tax (PAT) declined to about ₹85.27 crore from ₹93.1 crore, down 8.4% YoY. The company also disclosed healthy liquidity, with cash and cash equivalents of ₹854.7 crore as of June 30, 2026.

What changed in consolidated performance

The topline expansion in Q1 FY27 was accompanied by improved gross profitability. Consolidated gross profit increased to ₹385.6 crore from ₹276.0 crore, a 39.7% YoY rise. Gross margin improved to 73.4% from 68.4%, an expansion of 495 basis points. However, operating leverage did not translate into higher operating margins, as EBITDA margin compressed by about 260 basis points to 24.1%. The company attributed margin pressure to higher employee and other operating costs, particularly in a period when acquired businesses were consolidated. In the same context, the company’s strategy “Polymed 3.0” was linked to continued investment in R&D, new plants, and acquisition integration, which can raise near-term costs.

Organic growth versus reported growth

Poly Medicure disclosed an organic operating revenue figure of ₹453.1 crore for Q1 FY27. This implies 12.4% year-on-year growth on an organic basis, distinct from the 30.3% consolidated growth that includes the impact of acquisitions and consolidation. The difference between organic and reported growth is relevant in assessing how much of the quarter’s expansion came from existing operations versus added businesses. The company’s commentary also referred to strategic initiatives across product launches, R&D, and ESG commitments, positioning the quarter as part of a broader multi-year investment cycle. Investors often track this split to understand whether growth is being driven primarily by volumes and pricing in core lines or by inorganic additions.

Domestic and international revenue trend

The company reported that domestic revenue grew 16.2% YoY in Q1 FY27, while international revenue increased 36.7% YoY. The disclosure also included consolidated international revenue of ₹376.1 crore versus ₹275.1 crore in Q1 FY26. On the standalone side, domestic revenue was reported at ₹146.0 crore versus ₹125.7 crore, and international revenue at ₹281.8 crore versus ₹256.0 crore, alongside other operating revenue of ₹3.3 crore. This mix highlights the role of exports and overseas markets in driving overall growth during the quarter. It also helps explain why consolidated growth is higher than standalone growth, given the broader perimeter on consolidation.

Standalone financial snapshot and margins

Standalone revenue from operations increased 12.3% to ₹431.1 crore from ₹384.0 crore. Standalone gross profit rose 17.7% to ₹308.3 crore from ₹262.0 crore, and gross margin improved to 71.5% from 68.2%, an improvement of 330 basis points. Standalone operating EBITDA increased to ₹120.8 crore from ₹101.7 crore, up 18.8% YoY. Standalone EBITDA margin improved to 28.0% from 26.5%, and management noted this exceeded the guided range of 25%-27%. Standalone PAT was reported at ₹88.1 crore versus ₹87.9 crore, a 0.2% YoY increase, with PAT margin at 19.2% compared with 20.7%. Employee benefit expenses on standalone results rose to ₹88.9 crore from ₹69.2 crore, up 28.5% YoY, while R&D expenses increased to ₹7.9 crore from ₹7.3 crore.

Segment-wise revenue: what the mix shows

Poly Medicure provided segment-level disclosures for Q1 FY27 consolidated revenue. Infusion Therapy revenue was ₹259.2 crore, indicating 11.1% YoY growth. Orthopaedics revenue was ₹49.2 crore, described as a new segment from the Citieffe acquisition. Renal revenue was ₹43.2 crore, down 3.8% YoY. Cardiology revenue was ₹28.6 crore, showing 897% YoY growth.

Profit, margins and cost drivers

While gross margin improved sharply, the decline in EBITDA margin and PAT margin indicates that operating expenses rose faster than gross profit. Consolidated PAT margin fell to 15.3% from 20.9%, a contraction of 566 basis points. The company linked the EBITDA margin decline to higher employee and other operating costs during a quarter when acquired businesses were consolidated. Separately, the provided text also cites margin pressure from a 70.6% rise in employee benefit expenses and integration costs related to acquisitions such as PendraCare and Citieffe. These disclosures help reconcile why the quarter shows strong revenue growth but weaker year-on-year profit performance. They also explain why consolidated outcomes differ from standalone outcomes, where margins improved.

Liquidity position and investment agenda

Poly Medicure ended June 30, 2026 with cash and cash equivalents of ₹854.7 crore. The company flagged that liquidity matters because the “Polymed 3.0” strategy is built around continued investments in R&D, new plants, and the integration of acquisitions. This cash position provides operational flexibility for capex and integration activities, particularly in quarters where cost structures are adjusting. The company also reported consolidated total income of ₹558.8 crore, with other income contributing ₹33.4 crore, offering additional context on reported profitability for the period.

Corporate timeline: board approval and earnings call

Market chatter initially cited a consolidated net profit of ₹86 crore for Q1 FY27, with the note that it was not independently verified at that time. The company later said its board approved the unaudited financial results for the quarter ended June 30, 2026. The company also announced an earnings conference call scheduled for Monday, August 10, 2026, from 4:00 PM to 5:00 PM IST to discuss the unaudited Q1 FY27 results. The call announcement was filed with BSE and NSE on August 5, 2026. These dates matter because they mark the formal disclosure and management interaction points that investors track for commentary on margins, integration progress, and outlook.

Market impact and why the quarter matters

The quarter reinforces two simultaneous trends. First, revenue growth remains strong, led by international markets and contributions from acquisitions, taking consolidated revenue to ₹525.4 crore. Second, near-term profitability is sensitive to operating costs and integration effects, seen in the drop in consolidated EBITDA margin to 24.1% and the decline in PAT to about ₹85.27 crore. The company also noted that consolidated operating EBITDA margin was within the guided range of 23%-25%, while standalone margin exceeded its guidance range. The mix of improved gross margin and weaker PAT suggests that monitoring operating cost trajectories will be central for future quarters. The cash balance of ₹854.7 crore adds an important data point because it supports continued spending on R&D and capacity alongside integration.

Conclusion

Poly Medicure delivered a 30.3% YoY rise in consolidated revenue in Q1 FY27, but margins tightened and PAT fell 8.4% due to higher operating costs during acquisition consolidation. Next, investors will watch management commentary during the August 10, 2026 earnings call for updates on integration, cost control, and the investment roadmap tied to “Polymed 3.0.”